Overview Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants Status: Not yet recruiting Trial end date: 2026-12-01 Target enrollment: Participant gender: Summary The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants. Phase: Phase 3 Details Lead Sponsor: Elgan Pharma Ltd.